Session » Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis and Genetics

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 880

Role Of Urinary Podocyte Number and Urinary Podocalyxin Level As Biomarkers Of Glomerulonephritis In Systemic Lupus Erythematosus and ANCA-Associated Vasculitis

Abstract Number: 881

Time To Renal Flare and Renal Disease Activity Over a 1 Year Period Is associated With Urinary TWEAK Levels In Patients With Systemic Lupus Erythematosus

Abstract Number: 882

Association Of a Neutrophil Gene Signature Comprised Of Low Density Granulocyte (LDG)-Enriched Genes With Both Future Systemic Lupus Erythematosus Disease Activity and Poor Longterm Outcomes

Abstract Number: 883

Sex Bias In Autoimmune Diseases: Increased Risk Of 47,XXX In Systemic Lupus Erythematosus (SLE) and Sjögren’s Syndrome (SS) Supports The Gene Dose Hypothesis

Abstract Number: 884

Treatment Of Lupus Nephritis With Abatacept Plus Low-Dose Pulse Cyclophosphamide Followed By Azathioprine (the Euro-Lupus Regimen): Twenty-Four Week Data From a Double-Blind Controlled Trial

Abstract Number: 885

Fatigue In SLE Is Associated With Upregulation Of Interferon- Alpha Related Gene Transcripts

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.